14 results about "Neurotransmission" patented technology

The present invention provides a method and pharmaceutical composition for treating overactive bladder (OAB) and / or bladder pain syndrome (BPS) comprising a viral expression vector carrying a transcription cassette containing a transgene that inhibits / silences neurotransmission or synaptic transmission of an afferent neuron.

The present invention is directed to dihydroquinazoline, -benzothiazine and -benzoxazine derivatives, advantageously for use in the prevention or treatment of neurological, psychiatric and sleep disorders and diseases in which central orexin neurotransmission is impaired or in which central and peripheral orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds for use in the prevention and / or treatment of neurological disorders and diseases. The present invention is also directed to dihydroquinazoline, -benzothiazine and -benzoxazine derivatives and the use of these compounds as medicaments.

In nerve diseases, cell dysfunction due to amyloid aggregate accumulation in nerve cells has attracted attention, but dysfunction of nerve axons responsible for neurotransmission is also considered to be one of the causes. However, no therapeutic agent that focuses on the repair and maintenance of nerve axons has been found. An object of the present invention is to provide a therapeutic agent that activates oligodendrocytes having a function of preserving nerve axons.SOLUTION: Transcriptome analysis with a psychotropic drug is carried out using an oligodendrocyte marker as an indicator, and it is found that the combined use of DPZ and NFN characteristically increases the expression of a transcriptional factor OLIG1 inducing the differentiation-maturation of the oligodendrocyte. Moreover, the drug concentration at this time was much lower than the expected clinical dose. The combined use of NFN and DPZ was observed to improve spatial memory in the mouse Y-maze test. The combination of NFN and DPZ can provide a novel treatment for cognitive and memory functions associated with neurological disorders.SELECTED DRAWING: None

This invention belongs to the field of biomedicine and discloses estradiol derivatives or pharmaceutically acceptable salts thereof with the structure shown in Formula I: R is selected from R1, which is selected from F, Cl, Br, and I; L is selected from straight-chain or branched alkyl groups with 2 to 10 carbon atoms. This invention also discloses the use of the estradiol derivatives or pharmaceutically acceptable salts thereof in the preparation of drugs for treating depression and anxiety. Furthermore, this invention discloses the use of the estradiol derivatives or pharmaceutically acceptable salts thereof in the preparation of drugs targeting ERβ / SERT for treating depression and anxiety. The estradiol derivatives of this invention can simultaneously and effectively inhibit SERT and activate ERβ, thereby synergistically enhancing serotonergic neurotransmission and regulating neuroplasticity, and enhancing antidepressant efficacy through multi-target synergistic effects.

Provided are compounds of Formula I, described herein, processes for their preparation, their use as pharmaceuticals, and pharmaceutical compositions comprising them and intermediates used in their preparation. Compounds of Formula I are useful, for instance, in modulating dopamine and serotonin neurotransmission and treating disorders that may benefit from the same, such as schizophrenia and depression.

This application provides compounds of Formula I described herein, methods for their preparation, their use as pharmaceuticals, pharmaceutical compositions comprising them, and intermediates used in their preparation. Compounds of Formula I can be used, for example, to regulate dopamine and serotonin neurotransmission, and to treat conditions from which they may benefit, such as schizophrenia and depression.

Methods of use, pharmaceutical formulations, and labeled versions of compounds are provided of compounds that penetrate the blood-brain barrier and influence the balance of excitatory versus inhibitory neurotransmission by enantiomer selective modulation of glutamate and GABA metabolism. In some embodiments, a glutamatergic false neurotransmitter is S-2-methylglutamate (S-2MeGlu). In some embodiments a GABAergic false neurotransmitters is R-4 aminopentanomic acid (4APA) or S-4 aminopentanomic acid (S-4APA), with high penetration of the blood brain barrier and low toxicity, therein providing useful pharmacologic or imaging agents.

The present invention provides an implantable stimulation system having a stimulation unit coupled with a programmable controller, a stimulation circuit, and an array of electrodes arranged on a pair of flexible paddles. [Solution] A programmable controller is pre-programmed to activate an excitation electrode routine that selectively scans an electrode array with a series of directional current flows and optimizes electrode selection for use in stimulating nerves. The implantable stimulation system can be programmed to activate a first stimulation pulse sequence to induce a rapid erectile response corresponding to a first mode, a second nerve function recovery stimulation mode to restore function of neurotransmission in the cavernous nerve, a third penile function recovery mode to reduce penile fibrosis, and / or a fourth bladder nerve function recovery mode to restore function of neurotransmission in the nerves controlling the lower urinary tract.

Provided are compounds of Formula I, described herein, processes for their preparation, their use as pharmaceuticals, and pharmaceutical compositions comprising them and intermediates used in their preparation. Compounds of Formula I are useful, for instance, in modulating dopamine neurotransmission and treating disorders that may benefit from the same, such as schizophrenia and depression.

Provided are compounds of Formula I and Formula II as described herein, processes for their preparation, their use as medicaments, pharmaceutical compositions comprising them, and intermediates for their preparation. Compounds of Formula I and Formula II are useful, for example, to modulate dopamine and serotonin neurotransmission, and to treat conditions from which they may benefit, such as schizophrenia and depression.

Provided are compounds of Formula I and Formula II, described herein, processes for their preparation, their use as pharmaceuticals, and pharmaceutical compositions comprising them and intermediates used in their preparation. Compounds of Formula I and Formula II are useful, for instance, in modulating dopamine and serotonin neurotransmission and treating disorders that may benefit from the same, such as schizophrenia and depression.

The present invention provides a method and pharmaceutical composition for the treatment of overactive bladder (OAB) and / or bladder pain syndrome (BPS), comprising a viral expression vector having a transcription cassette containing one or more transgenes that inhibit / silence neurotransmission or synaptic transmission of afferent neurons.

The present invention relates to a novel chalcone derivative compound and a composition for the prevention or treatment of neurodegenerative diseases, comprising same as an active ingredient. The present invention can fundamentally eliminate the cause of neurotransmission dysfunction by simultaneously inhibiting the activities of two hyperactivated cholinesterases, unlike conventional symptomatic therapies that focus on the control of peripheral symptoms for various neurodegenerative diseases caused by a decrease in acetylcholine concentration, including Alzheimer's disease.

The present invention is directed to dihydroquinazoline, -benzothiazine and -benzoxazine derivatives, advantageously for use in the prevention or treatment of neurological, psychiatric and sleep disorders and diseases in which central orexin neurotransmission is impaired or in which central and peripheral orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds for use in the prevention and / or treatment of neurological disorders and diseases. The present invention is also directed to dihydroquinazoline, -benzothiazine and -benzoxazine derivatives and the use of these compounds as medicaments.